Dicerna Pharma Raises $25 Million
Dicerna Pharmaceuticals Inc., a Cambridge, Mass.-based RNA interference company, has raised $25 million in Series B funding. Domain Associates led the round, and was joined by return backers Oxford Bioscience Partners, Abingworth Management and Skyline Ventures. The company previously raised $21.4 million.
11 August 2010•4 mins read
